

Corrigendum

Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry

Clare Oni¹, Sheryl Mitchell², Katherine James³, Wan-Fai Ng^{2,4}, Bridget Griffiths², Victoria Hindmarsh², Elizabeth Price⁵, Colin T. Pease^{6,7}, Paul Emery^{6,7}, Peter Lanyon⁸, Adrian Jones⁸, Michele Bombardieri⁹, Nurhan Sutcliffe⁹, Costantino Pitzalis⁹, John Hunter¹⁰, Monica Gupta¹⁰, John McLaren¹¹, Annie Cooper¹², Marian Regan¹³, Ian Giles¹⁴, David Isenberg¹⁴, Vadivelu Saravanan¹⁵, David Coady¹⁶, Bhaskar Dasgupta¹⁷, Neil McHugh¹⁸, Steven Young-Min¹⁹, Robert Moots²⁰, Nagui Gendi²¹, Mohammed Akil²², Francesca Barone²³, Ben Fisher²³, Saaeha Rauz²³, Andrea Richards²⁴, Simon J. Bowman¹ on Behalf of the UK Primary Sjögren's Syndrome Registry*

Rheumatology 2016;55:544–552.
doi:10.1093/rheumatology/kev373

Further to publication of this paper the Authors have identified that although all 688 participants had a clinical diagnosis of primary Sjögren's Syndrome and 668 (97.1%) fulfilled the American-European Consensus Group (AECG) classification criteria, 20 patients (2.9%) did not have sufficient features to do so. This error arose from an incorrect assumption derived from the database during

analysis, for which the Authors apologize. There is no impact on the outcome or conclusions of the paper, but the methods have been amended accordingly online. The Authors also identified a small number of minor errors as follows: In the abstract the number eligible for the TEARS study is 46.3% not 31.6% (see Table 2). In Table 1: DMARD %=9.6; Pilocarpine or DMARD %=16.6; Unstimulated flow rate > 1.5mls/15 mins %=15.0; Low C3%=2.0; Low C4%=17.2; Lymphoma %=4.8 (see supplementary table).

¹Rheumatology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham, ²Rheumatology Department, Newcastle upon Tyne Hospitals NHS Foundation Trust, ³Interdisciplinary Computing and Complex BioSystems Research Group, School of Computing Science, Newcastle University, Newcastle, ⁴Musculoskeletal Research Group, Institute of Cellular Medicine & Newcastle NIHR Biomedical Research Centre for Ageing and Chronic Diseases, Newcastle University, Newcastle upon Tyne, ⁵Rheumatology Department, Great Western Hospitals NHS Foundation Trust, Swindon, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, ⁷NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, ⁸Rheumatology Department, Nottingham University Hospital, Nottingham, ⁹Department of Experimental Medicine and Rheumatology, Barts and the London NHS Trust and Barts and the London School of Medicine and Dentistry, London, ¹⁰Rheumatology Department, Gartnavel General Hospital, Glasgow, ¹¹Rheumatology Department, NHS Fife, Whyteman's Brae Hospital, Kirkcaldy, ¹²Rheumatology Department, Royal Hampshire

County Hospital, Winchester, ¹³Rheumatology Department, Royal Derby Hospital, Derby, ¹⁴Rheumatology Department, University College London Hospitals NHS Foundation Trust, London, ¹⁵Rheumatology Department, Queen Elizabeth Hospital, Gateshead, ¹⁶Rheumatology Department, Sunderland Royal Hospital, Sunderland, ¹⁷Rheumatology Department, Southend University Hospital, Southend, ¹⁸Rheumatology Department, Royal National Hospital for Rheumatic Diseases, Bath, ¹⁹Rheumatology Department, Portsmouth Hospitals NHS Trust, Portsmouth, ²⁰Rheumatology Department, Aintree University Hospitals, Liverpool, ²¹Rheumatology Department, Basildon Hospital, Basildon, ²²Rheumatology Department, Royal Hallamshire Hospital, Sheffield, ²³Centre for Translational Inflammation Research, University of Birmingham, Birmingham and ²⁴Department of Oral Medicine, Birmingham Dental Hospital, Birmingham, UK

Correspondence to: Simon J. Bowman, Rheumatology Department, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, UK. E-mail: simon.bowman@uhb.nhs.uk

*For other collaborators in the UK Primary Sjögren's Syndrome Registry, see Acknowledgements section.